Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond
CompanyDrug

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Inc. (NYSE: ABBV) announced the official launch in China of Epkinly (epcoritamab), a CD3×CD20 bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma…

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year

Company

Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results

Company

Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth

Company

Shanghai Pharmaceuticals Posts 13.11% YOY Revenue Growth in Q3 2023 Financials

Company

Takeda’s Global Revenues Grow: Strong Performance in Plasma Therapies and Gastroenterology

Company

BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights

Company

Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline

Company

Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff

Show More